Literature DB >> 31040232

Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations.

Murali Janakiram1,2, Milos D Miljkovic3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31040232      PMCID： PMC6518901          DOI： 10.3324/haematol.2019.217232

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.

Authors:  Takashi Ishida; Tatsuro Joh; Naokuni Uike; Kazuhito Yamamoto; Atae Utsunomiya; Shinichiro Yoshida; Yoshio Saburi; Toshihiro Miyamoto; Shigeki Takemoto; Hitoshi Suzushima; Kunihiro Tsukasaki; Kisato Nosaka; Hiroshi Fujiwara; Kenji Ishitsuka; Hiroshi Inagaki; Michinori Ogura; Shiro Akinaga; Masao Tomonaga; Kensei Tobinai; Ryuzo Ueda
Journal:  J Clin Oncol       Date:  2012-02-06       Impact factor: 44.544

2.  CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.

Authors:  Yuma Sakamoto; Takashi Ishida; Ayako Masaki; Takayuki Murase; Kentaro Yonekura; Yukie Tashiro; Masahito Tokunaga; Atae Utsunomiya; Asahi Ito; Shigeru Kusumoto; Shinsuke Iida; Ryuzo Ueda; Hiroshi Inagaki
Journal:  Blood       Date:  2018-06-21       Impact factor: 22.113

3.  European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.

Authors:  Pier Luigi Zinzani; Lionel Karlin; John Radford; Dolores Caballero; Paul Fields; Martine E D Chamuleau; Francesco d'Amore; Corinne Haioun; Catherine Thieblemont; Eva González-Barca; Carlos Grande García; Peter W Johnson; Gustaaf W van Imhoff; Thomas Ng; Karen Dwyer; Franck Morschhauser
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

4.  Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

Authors:  Kazuhito Yamamoto; Atae Utsunomiya; Kensei Tobinai; Kunihiro Tsukasaki; Naokuni Uike; Kimiharu Uozumi; Kazunari Yamaguchi; Yasuaki Yamada; Shuichi Hanada; Kazuo Tamura; Shigeo Nakamura; Hiroshi Inagaki; Koichi Ohshima; Hitoshi Kiyoi; Takashi Ishida; Kouji Matsushima; Shiro Akinaga; Michinori Ogura; Masao Tomonaga; Ryuzo Ueda
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

5.  North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies.

Authors:  Urvi A Shah; Elaine Y Chung; Orsi Giricz; Kith Pradhan; Keisuke Kataoka; Shanisha Gordon-Mitchell; Tushar D Bhagat; Yun Mai; Yongqiang Wei; Elise Ishida; Gaurav S Choudhary; Ancy Joseph; Ronald Rice; Nadege Gitego; Crystall Parrish; Matthias Bartenstein; Swati Goel; Ioannis Mantzaris; Aditi Shastri; Olga Derman; Adam Binder; Kira Gritsman; Noah Kornblum; Ira Braunschweig; Chirag Bhagat; Jeff Hall; Armin Graber; Lee Ratner; Yanhua Wang; Seishi Ogawa; Amit Verma; B Hilda Ye; Murali Janakiram
Journal:  Blood       Date:  2018-08-13       Impact factor: 22.113

6.  Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma.

Authors:  Adrienne A Phillips; Paul A Fields; Olivier Hermine; Juan C Ramos; Brady E Beltran; Juliana Pereira; Farooq Wandroo; Tatyana Feldman; Graham P Taylor; Ahmed Sawas; Jeffrey Humphrey; Michael Kurman; Junji Moriya; Karen Dwyer; Mollie Leoni; Kevin Conlon; Lucy Cook; Jason Gonsky; Steven M Horwitz
Journal:  Haematologica       Date:  2018-12-20       Impact factor: 9.941

7.  Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma.

Authors:  Masao Nakagawa; Roland Schmitz; Wenming Xiao; Carolyn K Goldman; Weihong Xu; Yandan Yang; Xin Yu; Thomas A Waldmann; Louis M Staudt
Journal:  J Exp Med       Date:  2014-12-08       Impact factor: 14.307

8.  Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.

Authors:  Akihiro Kitadate; Sho Ikeda; Fumito Abe; Naoto Takahashi; Norio Shimizu; Kosei Matsue; Hiroyuki Tagawa
Journal:  Haematologica       Date:  2017-10-12       Impact factor: 9.941
  8 in total
  1 in total

1.  Response to the comment: "Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations".

Authors:  Adrienne A Phillips
Journal:  Haematologica       Date:  2019-05       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.